Jul 26 2006
Cordis Corporation has announced plans to build a 180,000-square foot manufacturing facility, a development laboratory and a finished goods testing center in Cashel, Ireland. The company expects the new manufacturing facility to be operational during the first half of 2008. It will produce innovative products for interventional cardiology markets outside the United States.
"These new facilities are part of our continuing commitment to innovation and to the physicians who treat patients with coronary artery disease," said Rick Anderson, Company Group Chairman, Johnson & Johnson, and Worldwide Franchise Chairman, Cordis. "They are designed to support demand for the current Cypher family of drug-eluting stents, including the Cypher Sirolimus-eluting Coronary Stent and the Cypher Select Plus Sirolimus-eluting Coronary Stent, which has recently received the CE mark. It will also support innovative next-generation interventional and drug-device combination products."
The facility, which will showcase some of the most advanced production equipment available globally, will employ more than 400 people. Approximately 60 additional positions will be created at the finished goods testing center and at the development laboratory, which will help design and validate future generations of manufacturing technology and drug-device products.
http://www.cordis.com/